Apoptosis Suppression by Raf-1 and MEK1 Requires MEK- and Phosphatidylinositol 3-Kinase-Dependent Signals

Abstract

Two Ras effector pathways leading to the activation of Raf-1 and phosphatidylinositol 3-kinase (PI3K) have been implicated in the survival signaling by the interleukin 3 (IL-3) receptor. Analysis of apoptosis suppression by Raf-1 demonstrated the requirement for mitochondrial translocation of the kinase in this process. This could be achieved either by overexpression of the antiapoptotic protein Bcl-2 or by targeting Raf-1 to the mitochondria via fusion to the mitochondrial protein Mas p70. Mitochondrially active Raf-1 is unable to activate extracellular signal-related kinase 1 (ERK1) and ERK2 but suppresses cell death by inactivating the proapoptotic Bcl-2 family member BAD. However, genetic and biochemical data also have suggested a role for the Raf-1 effector module MEK-ERK in apoptosis suppression. We thus tested for MEK requirement in cell survival signaling using the interleukin 3 (IL-3)-dependent cell line 32D. MEK is essential for survival and growth in the presence of IL-3. Upon growth factor withdrawal the expression of constitutively active MEK1 mutants significantly delays the onset of apoptosis, whereas the presence of a dominant negative mutant accelerates cell death. Survival signaling by MEK most likely results from the activation of ERKs since expression of a constitutively active form of ERK2 was as effective in protecting NIH 3T3 fibroblasts against doxorubicin-induced cell death as oncogenic MEK. The survival effect of activated MEK in 32D cells is achieved by both MEK-and PI3K-dependent mechanisms and results in the activation of PI3K and in the phosphorylation of AKT. MEK and PI3K dependence is also observed in 32D cells protected from apoptosis by oncogenic Raf-1. Additionally, we also could extend these findings to the IL-3-dependent pro-B-cell line BaF3, suggesting that recruitment of MEK is a common mechanism for survival signaling by activated Raf. Requirement for the PI3K effector AKT in this process is further demonstrated by the inhibitory effect of a dominant negative AKT mutant on Raf-1-induced cell survival. Moreover, a constitutively active form of AKT synergizes with Raf-1 in apoptosis suppression. In summary these data strongly suggest a Raf effector pathway for cell survival that is mediated by MEK and AKT.Signal transduction downstream of the interleukin 3 (IL-3) receptor occurs through the activation of the two Ras effectors Raf-1 (9) and phosphatidylinositol 3-kinase (PI3K) (23) as well as independently of Ras through stimulation of JAK kinases and results in proliferation, differentiation, and cell survival (17). Published work has implicated both AKT and Raf-1 in cell survival signaling by IL-3. We have shown previously that expression of an oncogenic form of Raf-1 significantly delayed the onset of apoptotic cell death in the IL-3-dependent cell line 32D upon growth factor removal (12). Further work demonstrated that Raf-1 could synergize in this process with Bcl-2 (53), and dissection of this interaction indicated a role for Bcl-2 in the mitochondrial translocation of ...

ZBP-89-induced apoptosis is p53-independent and requires JNK

“…Collectively, these results demonstrate that inhibition of the ERK1/2 signaling pathway potentiates ZBP-89-induced apoptosis and is consistent with ERK1/2 having an antiapoptotic effect. 9 Although the kinetics of both stress kinases p38 and JNK best correlated with ectopic ZBP-89 expression and induction of apoptosis, p38 activation was not required for ZBP-89-induced apoptosis. Despite p38 kinases being required in some cells for p53-independent activation of apoptosis, 29,30 this pathway was clearly dispensable for ZBP-89-mediated apoptosis.…”

“…6,7 The mitogenic signaling cascade (Ras-MEK1-ERK) suppresses apoptosis through activation of both Raf and Akt/PKB. 8,9 In contrast, the stress-activated kinases, JNK and p38, are signaling pathways that mediate apoptosis initiated by UV irradiation, heat shock, chemotherapy and proinflammatory cytokines. [10][11][12][13] Recently, it has been shown that the phosphorylation and activation of JNK could be regulated either by activation of upstream kinases MKK4/7 or repression of upstream phosphatases.…”

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

“…33,34 Infection of cells with retroviral vectors FL5.12 and FL/Doxo cells were infected with retroviral vectors encoding WT or DN p53, constitutively active (CA) (DStuI-MEK-LIDEMANE) or DN MEK1 (MEKLIDA) or an empty retroviral vector (pLXSN), as previously described. [36][37][38] Stably infected (WT and DN p53-and pLXSN-transduced) cells were selected with IL-3 þ 2 mg ml À1 G418 (Geneticin, Invitrogen). 34 Stably infected (DN and CA MEK1, BRAF(WT):ER* and BRAF(V600E): ER*) cells were selected with IL-3 þ 2 mg ml À1 puromycin (Sigma-Aldrich).…”

Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells

“…Similarly, activation of the Ras/Raf/MEK/MAPK pathway is associated with protection of cells from apoptosis and inhibition of caspase-3 activation. [28][29][30][31] The MAPK pathway inhibits caspase-9 activity by direct phosphorylation. 32 Allan et al 32 showed that caspase-9 was phosphorylated at Thr 125, a conserved MAPK consensus site targeted by ERK2 in vitro, in a MEK-dependent manner in cells stimulated with epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol-13-acetate.…”